A novel surface plasmon resonance approach to assess anti‐dsDNA antibody kinetics and disease severity in systemic lupus erythematosus
Clinical & Translational Immunology · 2026-01 · 15 (1)
DOI: 10.1002/cti2.70072 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Translational Immunology, online erschienen am 14.01.2026. Verfasst von Carole Nagant und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immunology Department Centre Hospitalier Universitaire Brugmann, Université libre de Bruxelles Brussels Belgium. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objectives
Anti‐dsDNA antibodies are established biomarkers in systemic lupus erythematosus (SLE), yet the clinical utility of conventional assays remains limited by variable analytical performance. We evaluated a novel Fibre‐Optic Surface Plasmon Resonance (FO‐SPR) biosensor for real‐time profiling of anti‐dsDNA antibody–antigen interactions and investigated whether kinetic parameters are associated with disease severity, particularly lupus nephritis (LN).
Methods
Sera from 26 SLE patients (including 12 with LN), 14 disease controls and 16 healthy donors were analysed using FO‐SPR biosensors coated with biotinylated dsDNA. The sensors generated real‐time kinetic profiles from which maximum binding response ( B max ), association rate and dissociation constant were computed. FO‐SPR kinetic results were compared with a conventional chemiluminescent anti‐dsDNA assay (CLIA) and correlated with disease activity and renal involvement.
Results
The FO‐SPR platform enabled reliable detection of anti‐dsDNA antibodies and clearly distinguished SLE patients with renal involvement: Eight of 12 LN patients showed B max values above the 90th percentile of the non‐SLE control group. In these patients, kinetic parameters revealed high‐affinity anti‐dsDNA profiles characterised by significantly higher association rates and maximal shifts and lower dissociation constants. The AUC‐ROC for SPR‐derived affinity parameters was 0.82 ( P = 0.006), outperforming the CLIA assay to discriminate lupus patients with versus without nephritis. Furthermore, FO‐SPR binding responses correlated with disease activity score in LN.
Conclusion
This study highlights the value of an innovative FO‐SPR biosensor for real‐time characterisation of anti‐dsDNA antibody affinity. The kinetic profiles captured by this platform provide clinically relevant insights, particularly for distinguishing LN patients from other SLE phenotypes.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Immunology Department Centre Hospitalier Universitaire Brugmann, Université libre de Bruxelles Brussels Belgium.
- Laboratory of Translational Research, Centre Hospitalier Universitaire Brugmann, Université libre de Bruxelles Brussels Belgium.
- Nephrology Department Centre Hospitalier Universitaire Brugmann, Université libre de Bruxelles Brussels Belgium.
- Rheumatology Department Centre Hospitalier Universitaire Brugmann, Université libre de Bruxelles Brussels Belgium.
- Vixen Bio Ghent Belgium.
ORCID-Profile: Maxime Taghavi, Hasnae Ben Kacem Ziani
Zitieren
APA
Nagant, C., Taghavi, M., Ziani, H. B. K., Ghorra, N., Badot, V., Parmentier, S., & Corazza, F. (2026). A novel surface plasmon resonance approach to assess anti‐dsDNA antibody kinetics and disease severity in systemic lupus erythematosus. Clinical & Translational Immunology, 15(1). https://doi.org/10.1002/cti2.70072
Vancouver
Nagant C, Taghavi M, Ziani HBK, Ghorra N, Badot V, Parmentier S, et al. A novel surface plasmon resonance approach to assess anti‐dsDNA antibody kinetics and disease severity in systemic lupus erythematosus. Clinical & Translational Immunology. 2026;15(1). doi:10.1002/cti2.70072
BibTeX
@article{Nagant2026,
author = {Nagant, Carole and Taghavi, Maxime and Ziani, Hasnae Ben Kacem and Ghorra, Nathalie and Badot, Valérie and Parmentier, Sarah and Corazza, Francis},
title = {A novel surface plasmon resonance approach to assess anti‐dsDNA antibody kinetics and disease severity in systemic lupus erythematosus},
journal = {Clinical & Translational Immunology},
year = {2026},
volume = {15},
number = {1},
doi = {10.1002/cti2.70072}
}
EUVIMED